期刊
HUMAN VACCINES & IMMUNOTHERAPEUTICS
卷 18, 期 6, 页码 -出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/21645515.2022.2101334
关键词
Immunodeficiency; B-cell depletion; Rituximab; coronavirus evolution; COVID-19; SARS-CoV-2; human immunoglobulin; convalescent plasma; normal human intravenous immunoglobulin
资金
- Ministry of Science and Higher Education of the Russian Federation [075-15-2020-807]
The article discusses the case of a patient with long-term SARS-CoV-2 infection and secondary immunodeficiency. The analysis shows a mutation in the S-protein that may affect its binding ability to cellular receptors. Treatment with a COVID-19-globulin preparation resulted in rapid improvement, elimination of the virus, and passive immunization for at least 30 days.
The article highlights the course of long-term SARS-CoV-2 infection in a patient with a secondary immunodeficiency developed with B-cell-depleting therapy of the underlying disease. Analysis of the intrapatient virus evolution revealed an inpatient S:G75A mutation that alters the 72GTNGTKR78 motif of the S-protein, with a possible role in binding to alternative cellular receptors. Therapy with a ready-made COVID-19-globulin preparation (native human immunoglobulin G (IgG) derived from the plasma of convalescent COVID-19-patients) resulted in rapid improvement of the patient's condition, fast, and stable elimination of the virus, and passive immunization of the patient for at least 30 days. The results suggest the use of products containing neutralizing antibodies opens new prospects for treatment algorithms for patients with persistent coronavirus infection, as well as for passive immunization schemes for patients with a presumably reduced specific response to vaccination.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据